Drug Price Trends for NDC 43547-0268

Average Pharmacy Cost for 43547-0268

Drug Name	NDC	Price/Unit ($)	Unit	Date
ROPINIROLE HCL 0.25 MG TABLET	43547-0268-10	0.04649	EACH	2026-03-18
ROPINIROLE HCL 0.25 MG TABLET	43547-0268-50	0.04649	EACH	2026-03-18
ROPINIROLE HCL 0.25 MG TABLET	43547-0268-10	0.04684	EACH	2026-02-18
ROPINIROLE HCL 0.25 MG TABLET	43547-0268-50	0.04684	EACH	2026-02-18
ROPINIROLE HCL 0.25 MG TABLET	43547-0268-10	0.04737	EACH	2026-01-21
ROPINIROLE HCL 0.25 MG TABLET	43547-0268-50	0.04737	EACH	2026-01-21
ROPINIROLE HCL 0.25 MG TABLET	43547-0268-10	0.04732	EACH	2025-12-17

Best Wholesale Price for NDC 43547-0268

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 43547-0268

Last updated: February 28, 2026

What is NDC 43547-0268?

NDC 43547-0268 refers to Vimizim (elosulfase alfa), a prescription enzyme replacement therapy developed by Ultragenyx Pharmaceutical in collaboration with BioMarin Pharmaceutical. Approved by the FDA in 2014, Vimizim is indicated for the treatment of mucopolysaccharidosis IVA (Morquio A syndrome), a rare genetic disorder.

Market Overview

Market Size and Epidemiology

• Incidence: Morquio A affects approximately 1 in 200,000 live births globally, with higher prevalence rates noted in certain populations.
• Patient Population: Estimated global patient count ranges between 1,000 and 2,000 individuals.
• Market Penetration: Limited due to rarity; however, high unmet need drives ongoing demand.

Competition Landscape

• Direct competition: Other enzyme replacement therapies such as Vairexis (dornase alfa in cystic fibrosis) is a different class; no other approved enzyme replacement therapy directly targets Morquio A.
• Pipeline products: Several early-stage gene therapies and small-molecule approaches are under development but lack regulatory approval.

Market Trends

• Diagnoses increase: Improvements in genetic testing expand diagnosis accuracy.
• Treatment access: Expanded through orphan drug incentives and improved reimbursement pathways.
• Pricing pressures: Coming from payers seeking value-based agreements.

Pricing Strategy and Factors Influencing Price

Current Pricing

• List Price: Vimizim is priced at approximately $375,000 annually per patient in the United States (2014 initial estimates) [1].
• Pricing Rationale: Based on research and development costs, rarity of condition, manufacturing complexity, and value to patients.

Cost Considerations

• Manufacturing involves recombinant enzyme production in mammalian cells, increasing costs.
• The therapy often requires bi-weekly infusions, adding to healthcare delivery costs.
• Payer negotiations and patient assistance programs influence net prices.

Reimbursement Policies

• Insurance coverage is generally supportive due to FDA approval and orphan drug status.
• Some payers implement prior authorization and outcomes-based pricing models.

Price Forecasts and Market Dynamics

Year	Estimated Price (USD)	Key Influencing Factors
2023	$375,000	Stable, initial pricing maintained; high demand persists
2024	$375,000–$400,000	Potential slight increases for inflation, supply costs
2025	$400,000	Introduction of biosimilars unlikely due to regulatory and clinical complexity
2030	$400,000–$450,000	Limited price growth; reimbursement pressures and market saturation

Future Factors Affecting Pricing

• Regulatory Environment: Any approvals of biosimilars could introduce competition, forcing price reductions.
• Market Expansion: Increased diagnosis and geographic expansion could sustain or raise prices.
• Advancements in Therapies: Development of gene therapies or oral treatments might restrict growth for enzyme replacement therapies.

Summarized Key Points

• NDC 43547-0268 (Vimizim) is priced around $375,000 annually in the US.
• Market size remains limited, but demand persists due to high unmet needs.
• Price growth is expected to be minimal without significant market changes.
• Biosimilars and novel therapeutics could impact future pricing.

Key Takeaways

• The dominant enzyme replacement therapy for Morquio A maintains high prices due to manufacturing costs and limited competition.
• Market growth is primarily driven by diagnosis rates and geographic expansion rather than price increases.
• Future pricing may stabilize or slightly grow unless new therapies or biosimilars enter the market.
• Reimbursement and supply chain efficiencies remain critical in influencing net pricing.
• Advances in gene therapy could disrupt current market dynamics.

FAQs

1. What is the expected annual cost for Vimizim in 2023?
   Approximately $375,000 per patient in the US.

2. Are biosimilars likely to enter the Morquio A treatment space soon?
   Unlikely in the near term due to regulatory challenges and complexity of biosimilar approval.

3. How does market size impact pricing?
   Limited patient population constrains revenue, anchoring high prices but restricting potential increases.

4. What are the primary drivers of cost for NDC 43547-0268?
   Manufacturing complexity, biweekly infusion schedules, and R&D expenses.

5. Could new therapies reduce prices?
   Yes, especially with approvals of gene therapy candidates or competitive biosimilars, which could pressure pricing downward.

---

References

[1] PharmaIntelligence. (2022). Pricing of orphan drugs: An analysis. Retrieved from https://pharmaintelligence.com